Jump to ContentJump to Main Navigation
Show Summary Details
More options …

Clinical Chemistry and Laboratory Medicine (CCLM)

Published in Association with the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM)

Editor-in-Chief: Plebani, Mario

Ed. by Gillery, Philippe / Greaves, Ronda / Lackner, Karl J. / Lippi, Giuseppe / Melichar, Bohuslav / Payne, Deborah A. / Schlattmann, Peter


IMPACT FACTOR 2017: 3.556

CiteScore 2018: 2.44

SCImago Journal Rank (SJR) 2018: 1.191
Source Normalized Impact per Paper (SNIP) 2018: 1.205

Online
ISSN
1437-4331
See all formats and pricing
More options …
Volume 54, Issue 11

Issues

HbA1c: EQA in Germany, Belgium and the Netherlands using fresh whole blood samples with target values assigned with the IFCC reference system

Patricia Kaiser / Michael Spannagl / Christel van Campenhout / Yolande Lenga / Carla Siebelder / Cas Weykamp
Published Online: 2016-05-12 | DOI: https://doi.org/10.1515/cclm-2016-0123

Abstract

Background:

External quality assessment/proficiency test (EQA/PT) organizers play an important role in monitoring the performance of HbA1c measurements. With increasing quality of the assays, HbA1c is increasingly used for diagnosis of diabetes and the demands on EQA/PT organizers themselves are rising constantly. EQA organizers in Germany (INSTAND), Belgium (WIV/IPV), and the Netherlands (SKML) organized a program with commutable samples and target values assigned with the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) reference system. The aim of this project was to confirm the logistic feasibility of organizing synchronically in the three countries, an accuracy-based EQA program with fresh whole blood, to investigate the performance of HbA1c assays within and across countries and manufacturers, and to review the EQA acceptance limits.

Methods:

Throughout 2015, ten fresh whole blood samples were supplied to the participants. Aggregated results were evaluated according to the IFCC model for quality targets at four levels: overall, per country, per manufacturer, and per country per manufacturer.

Results:

Robust results in summer and winter demonstrated the feasibility of organizing an EQA with fresh whole blood samples in three countries. The overall performances, as well as the performance for each country were very similar: results fell within the IFCC criteria. Although substantial differences between results from different manufacturers were present, the performances of laboratories using tests of the same manufacturer were strikingly similar in the three countries, suggesting that the quality of HbA1c assays is for the most part manufacturer- related. The improved design of the EQA program also suggested that acceptance limits for performance can be reduced to approximately 8%.

This article offers supplementary material which is provided at the end of the article.

Keywords: EQA/PT; fresh whole blood; HbA1c; IFCC reference system

References

  • 1.

    American Diabetes Association. Standards of medical care in diabetes. 2011. Diabetes Care 2011;34(Suppl 1):S11–61.Google Scholar

  • 2.

    Sacks DB, Arnold M, Bakris GL, Bruns DE, Horvath AR, Kirkman MS, et al. Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. Clin Chem 2011;57:e1–47.Google Scholar

  • 3.

    Nathan D. On behalf of the Expert Committee. International Expert Committee on the role of A1c assay in the diagnosis of diabetes. Diabetes Care 2009;32:1327–34.Google Scholar

  • 4.

    Mosca A, Paleari R, Carobene A, Weykamp C, Ceriotti F. Performance of glycated hemoglobin (HbA1c) methods evaluated with EQAS studies using fresh blood samples: still space for improvements. Clin Chim Acta 2015;451:305–9.Google Scholar

  • 5.

    EN ISO/IEC 17043, Conformity assessment –General requirements for proficiency testing. International Organization for Standardization (Geneva, Switzerland).Google Scholar

  • 6.

    ISO 13528, Statistical methods for use in proficiency testing by interlaboratory comparisons. International Organization for Standardization (Geneva, Switzerland).Google Scholar

  • 7.

    Jeppson JO, Kobold U, Barr J, Finke A, Hoelzel W, Hoshino T, et al. Approved IFCC reference method for measurement of HbA1c in human blood. Clin Chem Lab Med 2002;40:78–89.Google Scholar

  • 8.

    Kaiser P, Akerboom T, Molnar P, Reinauer H. Modified HPLC-electrospray ionization/mass spectrometry method for HbA1c based on IFCC reference measurement procedure. Clin Chem 2008;54:1018–22.Google Scholar

  • 9.

    Evaluation of measurement data – Guide to the expression of uncertainty in measurement. BIPM Joint Comm Guides Metrol 100:2008.Google Scholar

  • 10.

    Weykamp C, John G, Gillery P, English E, Li Linong, Lenters-Westra E, et al. Investigation of 2 models to set and evaluate quality targets for HbA1c: biological variation and sigma-metrics. Clin Chem 2015;61:752–9.Google Scholar

  • 11.

    Richtlinie der Bundesärztekammer zur Qualitätssicherung laboratoriums-medizinischer Untersuchungen. Dtsch Arztebl 2014;38:A1583–618.Google Scholar

  • 12.

    Mosca A, Weykamp C. Feasibility of an EQAS for HbA1c in Italy using fresh blood samples. Clin Chem Lab Med 2014;52:e151–3.Google Scholar

  • 13.

    Weykamp C, Mosca A, Gillery P, Panteghini M. The analytical goals for hemoglobin A(1c) measurement in IFCC units and national Glycohemoglobin Standardization Program Units are different. Clin Chem 2011;57:1204–6.Google Scholar

  • 14.

    Miller WG, Jones GR, Horowitz GL, Weykamp C. Proficiency testing/external quality assessment: current challenges and future directions. Clin Chem 2011;57:1677–80.Google Scholar

About the article

Corresponding author: Dr. Patricia Kaiser, INSTAND e.V., Reference Laboratory, Düsseldorf, Germany, Fax: +49 211 15921356


Received: 2016-02-16

Accepted: 2016-04-07

Published Online: 2016-05-12

Published in Print: 2016-11-01


Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.

Research funding: None declared.

Employment or leadership: None declared.

Honorarium: None declared.

Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.


Citation Information: Clinical Chemistry and Laboratory Medicine (CCLM), Volume 54, Issue 11, Pages 1769–1775, ISSN (Online) 1437-4331, ISSN (Print) 1434-6621, DOI: https://doi.org/10.1515/cclm-2016-0123.

Export Citation

©2016 Walter de Gruyter GmbH, Berlin/Boston.Get Permission

Supplementary Article Materials

Citing Articles

Here you can find all Crossref-listed publications in which this article is cited. If you would like to receive automatic email messages as soon as this article is cited in other publications, simply activate the “Citation Alert” on the top of this page.

[1]
Hai-Jian Zhao, Tian-Jiao Zhang, Jie Zeng, Cui-Hua Hu, Rong Ma, and Chuan-Bao Zhang
Chinese Medical Journal, 2017, Volume 130, Number 9, Page 1079
[2]
Emma English and Erna Lenters-Westra
Critical Reviews in Clinical Laboratory Sciences, 2018, Page 1
[3]
Gunnar Nordin
Journal of Diabetes Science and Technology, 2018, Page 193229681878562
[4]
Kui Zhang, Yan Wang, Hongxia Wei, and Zhiye Xu
Clinical Therapeutics, 2017, Volume 39, Number 1, Page 220
[5]
Renata Paleari, Marta Strollo, Elena Guerra, Ferruccio Ceriotti, and Andrea Mosca
Clinica Chimica Acta, 2016, Volume 463, Page 27
[6]
P. Kaiser, D. Peetz, and M. Spannagl
Der Diabetologe, 2016, Volume 12, Number 7, Page 494

Comments (0)

Please log in or register to comment.
Log in